|Bid||70.47 x 800|
|Ask||70.57 x 800|
|Day's Range||66.83 - 70.70|
|52 Week Range||51.62 - 99.82|
|Beta (3Y Monthly)||2.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||99.00|
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the ongoing Phase 1 study evaluating single agent AG-881 in advanced glioma. AG-881 is an investigational, oral, selective, potent inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) and IDH2 enzymes and was designed for enhanced brain penetrance for development in IDH-mutant glioma. “With additional follow-up, the AG-881 Phase 1 dose-escalation data continue to show a favorable safety profile at the doses selected for the perioperative study.
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / U.S. equities saw losses on Tuesday as continued weakness in oil prices pressured energy stocks lower. Crude oil dropped for the 12th consecutive session, ...
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Biotech stocks may be nearing a significant break out using the SPDR Biotech ETF ( XBI) as a proxy. Esperion has broken out already after rising above technical resistance at $50.75. Now the chart suggests the stock may rise back to $69 to fill that gap, and should that happen it would result in a 17% gain from the current stock price of $58.86.
Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 3.55% and 8.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
– Updated Single Agent Ivosidenib Data in Previously Untreated Acute Myeloid Leukemia (AML) Patients from Phase 1 Study Chosen for Oral Presentation – – Updated Data from Phase.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.63. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / U.S. equities rose on Wednesday as a number of high profile companies reported upbeat corporate earnings that helped boost investor confidence. The Dow Jones ...
– Supplemental New Drug Application Submission for Single Agent TIBSOVO® (ivosidenib) in Newly Diagnosed IDH1m AML Patients Not Eligible for Standard Treatment Planned by the.
Short interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on October 24.
Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.
CAMBRIDGE, Mass., Oct. 18, 2018 -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.
Short interest is moderate for AGIO with between 5 and 10% of shares outstanding currently on loan. The net inflows of $2.47 billion over the last one-month into ETFs that hold AGIO are not among the highest of the last year and have been slowing.
NEW YORK, Oct. 04, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
As he prepares to step away from Agios — a company he said has almost unlimited potential and an environment that bypasses the confining corporate structures that have driven other local CEOs to startups — CEO David Schenkein is still mulling his future.
In this article I am going to calculate the intrinsic value of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by taking the foreast future cash flows of the company and discounting them backRead More...
Short interest is moderate for AGIO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average ...
Alkermes (ALKS) anticipates the net revenues in fiscal 2018 to be $957.0 million–$1.0 billion. Alkermes estimates the GAAP (generally accepted accounting principle) net income to be -$210.0 million to -$240.0 million, while the GAAP EPS is expected to be -$1.35 to -$1.55. Alkermes expects the non-GAAP net income to be between -$10 million and $20 million. The company also estimates the non-GAAP EPS to be between -$0.06 and $0.12.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Biotech Stocks Hitting 52-week highs on Sept. 4) Aptinyx Inc (NASDAQ: APTX ) Becton Dickinson and Co ...
Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein. Fouse, who rose through the ranks at Celgene to become president and chief operating officer before leaving the biotech company last year, is already a member of the Agios board. Schenkein, who took over as Agios CEO in 2009, will transition to the role of executive chairman and serve on the board's Science & Technology Committee, the biotech said.
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that effective February 1, 2019, David Schenkein, M.D., will transition to the role of executive chairman of the board of directors and serve as a member of the board’s Science & Technology Committee, after a successful decade-long tenure as chief executive officer. Jacqualyn (“Jackie”) Fouse, Ph.D., a member of the company’s board, has been named as Agios’ next chief executive officer.